Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome

Muscle and Nerve

Volumn 35, Issue 2, 2007, Pages 178-183

  Oh, Shin J ^a   Hatanaka, Yuki ^a   Claussen, Gwen C ^a   Sher, Emanuele ^b  

^a The University of Alabama at Birmingham   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Electrodiagnosis; Lambert Eaton myasthenic syndrome; Neuromuscular transmission disorder; Seronegative LEMS; Seropositive LEMS; Voltage gated calcium channel antibody

Indexed keywords

ANTIBODY; VOLTAGE GATED CALCIUM CHANNEL;

ACTION POTENTIAL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; EATON LAMBERT SYNDROME; ELECTROPHYSIOLOGY; FACILITATION; FEMALE; HUMAN; MALE; NERVE STIMULATION; PRIORITY JOURNAL;

ACTION POTENTIALS; ANTIBODIES; CALCIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRIC STIMULATION; ELECTROMYOGRAPHY; FEMALE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; MUSCLE, SKELETAL;

EID: 33846963195     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20672     Document Type: Article

References (13)

1. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612-613.
2. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in Lambert-Eaton myasthenic syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
3. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35-42.
4. Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, Yoshimura T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002;59:1773-1775.
5. Oh SJ. Electromyography. Neuromuscular transmission studies. Baltimore, MD: Williams & Wilkins; 1988.
6. Oh SJ. Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989;12:464-469.
7. Oh SJ. Electrophysiological characteristics in seronegative myasthenia gravis. Ann NY Acad Sci 1993;681:584-587.
8. Oh SJ, Head T, Fesenmeier J, Claussen G. Peroneal nerve repetitive nerve stimulation test: its value in diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Muscle Nerve 1995;18:867-873.
9. Oh SJ, Kim DE, Kuruoglu R, Brooks J, Claussen GC. Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1996;19:903-906.
10. Oh SJ, Kurokawa K, Claussen GC, Ryan HF. Electrophysiological criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515-520.
11. Sher E, Gotti C, Canal N, Scoppetta C, Piccolo G, Evoli A. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 1989;2:640-643.
12. Wirtz PW, Nijnuis MG, Sotodeh M, Willems L, Brahim JJ, Putter H, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250:698-701.
13. Wirtz PW, Wintzen AR, Verschuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 2005;32:226-229.